Deutsche Bank Raises Achillion Price Target 183%

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and raised the price target from $6 to $17.

In the past, key concerns surrounded clinical and management execution. However, analyst Alethia Young writes that execution is improving and the appointment of a new CMO increases management prowess.

“Every 10% POS [probability of success for the nuke] is worth $5-6/sh. We currently assume Achillion peak sales of $3B (10% peak share) launching in ‘18 and a 5% lower price point vs. GILD,” says Young.

Deutsche Bank’s base case assumes a 40 percent chance of success.

Related Link: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

The report briefly touches on Achillion as a takeover target.

“We have always believed that having a nuke will be essential to a competitive long-term regimen in HCV. Currently only GILD, Merck, and ACHN have nukes that are in development or on market… [acquisition speculation] occurred after Idenix was acquired by Merck for ~$4B at similar stage as ACHN’s fall data readout.”

The $17 price target is based on a DCF with a 12 percent discount rate. Shares of Achillion were last up seven percent in pre-market trading to $9.90.